A detailed history of Alpha Centric Advisors LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 100,000 shares of ROIV stock, worth $1.12 Million. This represents 0.98% of its overall portfolio holdings.

Number of Shares
100,000
Previous 88,000 13.64%
Holding current value
$1.12 Million
Previous $930,000 24.09%
% of portfolio
0.98%
Previous 0.77%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$10.17 - $12.5 $122,040 - $150,000
12,000 Added 13.64%
100,000 $1.15 Million
Q2 2024

Jul 25, 2024

SELL
$10.36 - $11.74 $20,720 - $23,480
-2,000 Reduced 2.22%
88,000 $930,000
Q1 2024

Apr 24, 2024

BUY
$9.87 - $11.8 $345,450 - $413,000
35,000 Added 63.64%
90,000 $948,000
Q4 2023

Feb 14, 2024

BUY
$8.38 - $11.58 $167,600 - $231,600
20,000 Added 57.14%
55,000 $617,000
Q3 2023

Nov 13, 2023

BUY
$9.76 - $13.19 $341,600 - $461,650
35,000 New
35,000 $408,000

Others Institutions Holding ROIV

About Roivant Sciences Ltd.


  • Ticker ROIV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 704,382,976
  • Market Cap $7.86B
  • Description
  • Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...
More about ROIV
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.